izpis_h1_title_alt

Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts
ID Sturtzel, Caterina (Author), ID Zajec, Živa (Author), ID Dernovšek, Jaka (Author), ID Tomašič, Tihomir (Author), ID Taschner-Mandl, Sabine (Author), ID Distel, Martin (Author), et al.

.pdfPDF - Presentation file, Download (5,10 MB)
MD5: D5259D55451AA25C4EBB20F6EF2066EB
URLURL - Source URL, Visit https://www.nature.com/articles/s41698-023-00386-9 This link opens in a new window

Abstract
Zebrafish xenotransplantation models are increasingly applied for phenotypic drug screening to identify small compounds for precision oncology. Larval zebrafish xenografts offer the opportunity to perform drug screens at high-throughput in a complex in vivo environment. However, the full potential of the larval zebrafish xenograft model has not yet been realized and several steps of the drug screening workflow still await automation to increase throughput. Here, we present a robust workflow for drug screening in zebrafish xenografts using high-content imaging. We established embedding methods for high-content imaging of xenografts in 96-well format over consecutive days. In addition, we provide strategies for automated imaging and analysis of zebrafish xenografts including automated tumor cell detection and tumor size analysis over time. We also compared commonly used injection sites and cell labeling dyes and show specific site requirements for tumor cells from different entities. We demonstrate that our setup allows us to investigate proliferation and response to small compounds in several zebrafish xenografts ranging from pediatric sarcomas and neuroblastoma to glioblastoma and leukemia. This fast and cost-efficient assay enables the quantification of anti-tumor efficacy of small compounds in large cohorts of a vertebrate model system in vivo. Our assay may aid in prioritizing compounds or compound combinations for further preclinical and clinical investigations.

Language:English
Keywords:cancer models, phenotypic screening
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2023
Number of pages:16 str.
Numbering:Vol. 7, art. 44
PID:20.500.12556/RUL-146346-31b66c38-f629-0ade-335e-3ea531c9b90b This link opens in a new window
UDC:615.4:54:616-006
ISSN on article:2397-768X
DOI:10.1038/s41698-023-00386-9 This link opens in a new window
COBISS.SI-ID:153170179 This link opens in a new window
Publication date in RUL:24.05.2023
Views:546
Downloads:65
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:npj precision oncology
Shortened title:npj precis. oncol.
Publisher:Springer Nature, University of Minnesota, The Hormel Institute
ISSN:2397-768X
COBISS.SI-ID:526771225 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:fenotipski pregled, cebrica, tumorske celice, presajanje zdravil, ksenografti celic, onkologija, farmacevtska kemija, tumorji

Projects

Funder:Other - Other funder or multiple funders
Funding programme:Austrian Research Promotion Agency (FGG)
Project number:7940628 533
Acronym:Danio4Can

Funder:Other - Other funder or multiple funders
Funding programme:Alex’s Lemonade Stand Foundation

Funder:Other - Other funder or multiple funders
Funding programme:Vienna Science and Technology Fund (WWTF)
Project number:LS18-111

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:J1-1717
Name:Razvoj novih zaviralcev Hsp90 s protitumornim delovanjem

Funder:Other - Other funder or multiple funders
Funding programme:BMBWF, OeAD
Project number:SI 29/2023

Funder:Other - Other funder or multiple funders
Funding programme:Austrian Academy of Sciences, DOC fellowship

Funder:EC - European Commission
Funding programme:H2020
Project number:116064
Name:ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064
Acronym:ITCC-P4

Funder:Other - Other funder or multiple funders
Funding programme:Sanofi

Funder:Other - Other funder or multiple funders
Funding programme:MedUni Wien, Comprehensive Cancer Center, Forschungsförderung der Initiative Krebsforschung
Acronym:PECAZA

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back